STAT June 21, 2024
Adam Feuerstein

Sarepta Therapeutics always wins. That was a given, even before the Food and Drug Administration expanded approval of the company’s Duchenne muscular dystrophy drug on Thursday. Will boys with Duchenne also benefit? I hope they do, but it’s uncertain. And is this a good look for the FDA? No, it is not.

There is much to unpack from the unilateral decision by Peter Marks, the FDA’s top regulator of gene...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs
Public Health Matters Video: Walmart is Elevating Specialty Pharmacy Services and Enriching HIV Care
Demand for hospital pharmacists dips
Pfizer, Valneva inch closer to FDA approval of 1st Lyme disease vaccine
New Gene Therapy for Muscular Dystrophy May Facilitate Development of Others

Share This Article